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Abstract
 
Branch points and flexures in the high pressure arterial system have long been recognized as
sites of unusually high turbulence and consequent stress in humans are foci for atherosclerotic
lesions. We show that mice that are homozygous for a null mutation in the gene encoding an
endogenous antiinflammatory cytokine, interleukin 1 receptor antagonist (IL-1ra), develop lethal
arterial inflammation involving branch points and flexures of the aorta and its primary and sec-
ondary branches. We observe massive transmural infiltration of neutrophils, macrophages, and
CD4
 
1
 
 T cells. Animals appear to die from vessel wall collapse, stenosis, and organ infarction or
from hemorrhage from ruptured aneurysms. Heterozygotes do not die from arteritis within a
year of birth but do develop small lesions, which suggests that a reduced level of IL-1ra is insuffi-
cient to fully control inflammation in arteries. Our results demonstrate a surprisingly specific
role for IL-1ra in the control of spontaneous inflammation in constitutively stressed artery
walls, suggesting that expression of IL-1 is likely to have a significant role in signaling artery
wall damage.
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Introduction
 
IL-1 is a primary inflammatory cytokine (for review see
reference 1). Its two forms, IL-1
 
a
 
 and IL-1
 
b
 
, are products
of adjacent but highly divergent genes. Both forms bind
with high affinity and signal only through the type I IL-1
receptor (2, 3). Locally applied IL-1 causes all the features
of inflammation: it activates prostaglandin synthesis (4) and
induces nitric oxide synthase in smooth muscle (5), secre-
tion of proteolytic enzymes (6), and the release of further
inflammatory mediators, notably IL-6 (7) and chemokines
(8). IL-1 triggers increased surface availability of adhesion
molecules on endothelial cells and leukocytes (9). The
combination of chemokine secretion and induction of ad-
hesion molecules stimulates leukocyte extravasation and tis-
sue infiltration.
IL-1ra (receptor antagonist; mouse locus, 
 
Il1rn
 
)
 
1
 
 is a struc-
tural homologue of IL-1 (10) and occupies the type I IL-1
receptor with higher affinity and an association rate constant
similar to that of IL-1
 
a
 
 and IL-1
 
b
 
 (11) but appears to be un-
able to recruit the IL-1 receptor accessory protein, which in
turn is required to mediate intracellular signaling (12, 13).
IL-1ra thus antagonizes productive IL-1 binding. IL-1ra and
IL-1
 
b
 
 are often coexpressed by activated monocytes. Though
the relative secreted concentrations of IL-1ra and IL-1
 
b 
 
are
modulated (14, 15), IL-1ra is typically produced in much
greater abundance. To produce a large biological effect, it
appears that only a small proportion of IL-1 receptors need
be occupied by IL-1 (for review see reference 16). It follows
that the local ratio of available agonist/antagonist might de-
termine the extent of IL-1 receptor signaling rather than the
concentration of agonist alone, and it has been proposed that
this ratio is an important determinant in the course of in-
flammatory diseases (17).
Two forms of IL-1ra protein have been reported in both
mice and humans. One form is secreted (sIL-1ra; references
10 and 18), and one lacks the signal sequence and is retained
within the cytoplasm of intact cells (icIL-1ra; references 19
and 20). Other nonsecreted forms have been reported in
humans only (21, 22). The alternative forms result from the
activity of two promoters, differential splicing of the pri-
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mary transcripts, and the use of different translational initia-
tion sites. With the exception of the recently described 16-kD
form of IL-1ra, which has reduced affinity for the receptor
(22), all forms of IL-1ra are biochemically equivalent. sIL-1ra
is secreted by activated monocytes and macrophages (20).
sIL-1ra in the circulation is probably maintained by consti-
tutive secretion from hepatocytes, and its concentration is in-
creased during the acute phase response (23). icIL-1ra mRNA
is also present inducibly in monocytes (20) but is abundant in
epithelial cells, from which it was originally identified (19).
It has been proposed that in atherosclerosis, IL-1 and other
inflammatory cytokines are secreted by foam cells (mac-
rophages) in atherosclerotic plaques, as well as by vascular
endothelial and smooth muscle cells (for review see refer-
ence 24). IL-1 stimulates the local secretion of platelet-
derived growth factor, which in turn acts as a mitogen for
smooth muscle cells and fibroblasts (25) and thus may serve
as a mediator in the invasion of the damaged vessel intima
by hypertrophic smooth muscle. The superficial prolifera-
tion of matrix-depositing cell types appears to permit the
accumulation of further atherogenic material into the grow-
ing plaque (24). IL-1ra mRNA and protein is present in
human vascular cells within and in the vicinity of plaques
(Francis, S., personal communication). A crucial role in ar-
terial biology for IL-1ra or a closely linked gene is also sug-
gested by the strong genetic association of single vessel cor-
onary artery disease with the rarer allele of the human IL-1ra
gene (26), though the functional difference between the two
alleles in this context remains to be explored.
Two previous reports of IL-1ra gene disruption (27, 28)
have shown that IL-1ra–deficient animals are developmen-
tally normal but have a lower mean postnatal growth rate
than their wild-type or heterozygous littermates. No other
spontaneous pathology has so far been reported. 
 
Il1rn
 
2
 
/
 
2
 
animals are hypersensitive to bacterial LPS and to fever in-
duced by sterile local inflammation (28). Circulating levels
of IL-1
 
b
 
 were also reduced in LPS-stimulated mice com-
pared with wild-type animals (27), implying some level of
negative feedback in the IL-1 system. IL-1ra–deficient
mice had an enhanced ability to clear the intracytoplasmic
parasite 
 
Listeria monocytogenes
 
, suggesting that the macrophages
of mice deficient in IL-1ra are more readily activated by
endogenously generated IL-1 in the absence of IL-1ra (27).
It thus appears that in nature, IL-1ra is part of a balance that
is achieved between the beneficial excitability of the pri-
mary immune system and its potentially devastating auto-
toxic effects.
 
Materials and Methods
 
Generation of the Il1rn-null Allele in Mice.
 
A genomic 
 
l
 
 clone
spanning 
 
1
 
0.1 to 
 
1
 
14.6 kb (as defined from the first nucleotide
of sequence available from EMBL/GenBank/DDBJ under acces-
sion no. L32838; reference 18) was identified in a strain 129 mouse
library by hybridization with human IL-1ra cDNA and genomic
clones. E14 TG2A embryonic stem (ES) cells were transfected as
described previously (29) with a replacement construct that con-
tained homologous arms consisting of nucleotides 916 to 3,530
 
and 4,791 to 
 
z
 
11,800 relative to L32838. The arms flanked a
polyadenylation sequence, an inverted 
 
aph
 
 gene driven by the
human 
 
b
 
-actin promoter and a modified pBluescript vector (see
Fig. 1 a; reference 30). The promoter was modified to remove an
endogenous NotI site. Resistant colonies were selected with
G418 and genomic DNA from expanded clones was screened for
homologous recombination on Southern blots with the 5
 
9
 
 and 3
 
9
 
flanking probes (see Fig. 1 a). ES cells were microinjected into
C57BL/6 blastocysts, and chimeric mice were derived. Chimeras
were bred with outbred MF1 albino females. With the exception
of the confirmatory study, results presented are from the descen-
dants of a single chimera and a single MF1 from the Edinburgh
MF1 colony. The confirmatory colony was founded from a chi-
mera derived from an independent G418-resistant ES colony.
The chimera was backcrossed three times onto 129/Ola (Harlan
UK) and mated with an MF1 female from the stock in Sheffield.
 
Genotype Screening.
 
Initial screening of ES cell lines and test
screens of DNA from founders (data not shown) and from se-
lected progeny (see Fig. 1, b and c) were by Southern blot analy-
sis with flanking probes containing nucleotides 46 to 567 and
 
z
 
13,300 to 
 
z
 
14,600 (AccI–NotI). The carriage of wild-type and
null alleles was subsequently followed by allele-specific PCR
analysis of DNA extracted from ear clippings.
 
Detection of Arteritis.
 
Live animals were killed either by over-
dosing with anesthetic and exsanguination from the heart or by
cervical dislocation. Spontaneously dead or killed animals were
dissected by a longitudinal cut into the peritoneum and thoracic
cavity and were immersed in 4% formaldehyde for 
 
.
 
48 h. After
dehydration and embedding in paraffin, 5-
 
m
 
m sections were
stained with hematoxylin and eosin. Blocks of tissue that were
examined included (a) the aortic arch and the mediastinal arteries,
(b) the abdominal aorta from the diaphragm to the iliac bifurca-
tion, and (c) the arteries of the leg. All other tissues were sampled
in a cohort of 53 animals, including 42
 
 Il1rn
 
2
 
/
 
2
 
 and 11 
 
Il1rn
 
1
 
/
 
2
 
mice. For the final 30 animals, only the arteries were examined.
 
Immunohistology.
 
Lesional sites were discovered by cutting
5-
 
m
 
m frozen sections from candidate tissue and staining every
20th section with hematoxylin and eosin. Sections were stored at
 
2
 
80
 
8
 
C and fixed with acetone after drying. To detect intracellu-
lar IL-1
 
b
 
, the sections were first treated with a solution of 0.1%
saponin in PBS, a procedure that did not interfere with subse-
quent detection of either CD4 or the F4/80 antigen. Serial sec-
tions were stained with mAbs to F4/80 antigen, CD4, CD8, CD19
(PharMingen), IL-1
 
b
 
 (R & D Systems, Inc.), and with control
nonspecific mAbs. In Fig. 4, a–d, primary antibodies were de-
tected with a two-layer biotinylated secondary antibody/peroxi-
dase-conjugated avidin system (Vector Labs., Inc.) with final oxi-
dation of diaminobenzidine to yield a brown pigment. In Fig. 4,
e–h, IL-1
 
b
 
–containing cells were first detected as before but with
nickel salt added to the substrate as described by the manufactur-
ers, to yield a darker pigment. F4/80 antigen or CD4 was then
also detected with a two-layer biotinylated secondary antibody/
alkaline phosphatase–conjugated avidin system (Vector Labs.,
Inc.) and the substrate Vector Red (Vector Labs., Inc.) in the
presence of the selective phosphatase inhibitor levamisole (Vector
Labs., Inc.), as described by the manufacturer. Vascular tissue gave
no significant cellular red staining in the absence of a primary an-
tibody.
 
Pathogen Screening.
 
Five 
 
Il1rn
 
2
 
/
 
2
 
 mice (four of five severely arter-
itic) were raised under specific pathogen–free (SPF) conditions. Se-
rum was tested at the Diagnostic Service, Royal Veterinary Col-
lege, London for evidence of infection with the following viruses:
adeno-, cytomegalo-, ectromelia (mouse pox), hantaan, hepatitis, 
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K-, lymphocytic choriomeningitis, minute, parainfluenza-, pneu-
monia, polyoma-, Sendai, and Theiler’s viruses; epizootic diar-
rhea of infant mice (mouse rotavirus), and reovirus 3, and for other
agents, 
 
Clostridium piliformis
 
, 
 
Mycoplasma pulmonis, 
 
and 
 
Encephalito-
zoon cuniculi
 
. All results were negative. Serum from five 
 
Il1rn
 
2
 
/
 
2
 
mice (four of five overtly diseased) were screened for mouse 
 
Chlamy-
dia
 
 by Dr. B. Thomas (St. Mary’s Hospital, London) and found
negative. Fecal samples were screened by a PCR-based detection
method (31) in our laboratories and the laboratory of Professor L.
Riley (University of Missouri, Columbia, MO) for colonization
by 
 
Helicobacter 
 
spp.
 
Results
 
Characterization of the IL-1ra-null Allele.
 
The event lead-
ing to the inactivation of the IL-1ra gene was demonstrated
by showing that the replacement vector was physically linked
to uninvolved markers on both flanks (Fig. 1, a–c). Homol-
ogous recombination would result in the fusion of vector-
derived sequence with the open reading frame in the mid-
dle of the single folding domain of IL-1ra (in exon 3),
which is codon 77 of the mature sIL-1ra and codon 82 of
icIL-1ra (18, 20). No functional IL-1ra protein would be
expected from the engineered allele that we describe. To
ensure that the phenotype that we observed did not result
from modulation of the adjacent gene of the IL-1 gene
family, 
 
Il1l1
 
 (Barton, J., and M. Nicklin, unpublished data;
available from EMBL/GenBank/DDBJ under accession no.
AJ250429), we performed reverse transcription and PCRs
on total RNA from LPS-stimulated peritoneal macrophages
of both wild-type and 
 
Il1rn
 
2
 
/
 
2
 
 mice. No transcript was found
in either, although IL-1ra mRNA could be found in
mRNA from the wild-type animals and IL-1–like protein
1 mRNA was detected in RAW 264.7 macrophages.
 
Il1rn
 
2
 
/
 
2
 
, 
 
Il1rn
 
1
 
/
 
2
 
, and 
 
Il1rn
 
1
 
/
 
1
 
 offspring were produced in
the expected Mendelian ratios. Activated macrophages from
 
Il1rn
 
2
 
/
 
2
 
 mice did not contain detectable IL-1ra mRNA (Fig.
1 d) nor produce IL-1ra protein (Fig. 1 e). Both sexes of
 
Il1rn
 
2
 
/
 
2
 
 mice were fertile, and 
 
Il1rn
 
2
 
/
 
2
 
 intercrosses were suc-
cessful. We determined the mean body mass at between 27
and 33 d of age in 53 litters that contained 
 
Il1rn
 
2
 
/
 
2
 
 and
 
Il1rn
 
1
 
/
 
2
 
 mice. In 37/53 litters, the mean mass of the ho-
mozygotes was less than the mean of the heterozygotes (
 
x
 
2
 
 
 
5
 
8.3, 
 
P 
 
, 
 
0.005), in agreement with previous reports (27, 28).
 
Longevity of Il1rn
 
2
 
/
 
2
 
 Mice and Incidence of Arteritis. Il1rn
 
2
 
/
 
2
 
and 
 
Il1rn
 
1
 
/
 
2
 
 mice were crossed to produce approximately
equal numbers of 
 
Il1rn
 
2
 
/
 
2
 
 and 
 
Il1rn
 
1
 
/
 
2
 
 offspring. 18 litters
containing
 
 Il1rn
 
1
 
/
 
2
 
 and 
 
Il1rn
 
2
 
/
 
2
 
 animals were monitored
up to 550 d from birth (Fig. 2); 51/55 
 
Il1rn
 
2
 
/
 
2
 
 mice died
or were culled on humane grounds (93%), and the median
age of death was 159 d, compared with 6/37 (16%) het-
erozygotes. Between 200 and 400 d from birth, the excess
mortality exceeded 10. Autopsies on 46 
 
Il1rn
 
2
 
/
 
2
 
 mice that
had become ill (from this group and other litters) revealed
arterial inflammation in 43 and ruptured aneurysms or indi-
cations of internal hemorrhage in 16. 2 of the 3 mice in
which arteritis was not overt showed secondary signs of the
disease, namely ischemic cardiomyopathy and interstitial
Figure 1. Molecular analysis of the Il1rn-null allele. (a) Structure of the
Il1rn knockout construct. Top line: the genomic structure of the wild-
type mouse Il1rn allele (18). Positions of the two ApaI and two BstEII re-
striction sites within the region are indicated above the line. The exon
structure is indicated by boxes, the coding region by filled areas. Exons
are labeled below the line, and the two flanking probes are shown. The
homologous arms used in preparing the knockout construct are indicated
between the two lines. Bottom line: expected structure of the null allele
generated by homologous recombination through both flanking arms.
The thickened portion represents the knockout vector and contains the
aph (aminoglycoside phosphotransferase) gene driven by a b-actin pro-
moter (b-Neo). The position of the vector b-lactamase gene (Bla) is indi-
cated. Restriction sites used in the screening of the genomic DNA are in-
dicated above the line. (b) Southern blot hybridization of mouse liver
DNA from littermates, digested with BstEII and probed with the 59
flanking probe. Lane 1, Il1rn2/2; lanes 2, 3, and 4, Il1rn1/2; and lanes 5
and 6, Il1rn1/1 animals. (c) Southern blot hybridization of high-molecu-
lar-mass mouse spleen DNA from littermates, digested with ApaI and
probed with the 39 flanking probe. Lane 1, Il1rn2/2; lanes 2 and 4, Il1rn1/1;
and lanes 3 and 5, Il1rn1/2 animals. (d) Total RNA from z106 peritoneal
macrophages, cultured for 4 h in the presence of 0.1 mg/ml Escherichia coli
LPS (Sigma Chemical Co.), was sequentially hybridized with (top) a
probe (nucleotides 50–726) spanning the coding sequence of the mouse
IL-1ra cDNA (18) (the sequence is interrupted at nucleotide 400 in the
null allele), and (bottom) a control cDNA probe for mouse IL-1b. Lanes
1 and 2 contain RNA from Il1rn1/1 and lanes 3 and 4 are from Il1rn2/2
mice. (e) Immunoprecipitation with goat anti–mouse IL-1ra (R & D Sys-
tems, Inc.) of secreted IL-1ra from z106 peritoneal macrophages cultured
for 7.5 h in the presence of 0.1 mg/ml E. coli LPS and labeled for 3 h in 4 ml
serum-free RPMI with 67 mCi/ml [35S]methionine. Immune complexes
were precipitated with protein A–Sepharose. Cells are from Il1rn2/2
(lanes 1 and 4) and Il1rn1/1 (lanes 2 and 3) mice.306 Arteritis in IL-1ra–deficient Mice
nephritis, probably due to undetected coronary and renal
artery lesions, respectively.
We confirmed the existence of arteritis in a second line,
derived from a different G418-resistant ES colony, where
we found that two out of four homozygous animals had
overt arteritis at 135 d and another animal had ischemic
cardiomyopathy, which we have frequently found associ-
ated with aortic root inflammation in our main colony.
Effect of Lineage on Age of Onset in Il1rn2/2 Mice. Our
main colony, which was initiated by breeding a chimera
with an outbred mother, could therefore contain up to
three distinct haploid genotypes. The age of presentation of
histologically confirmed arteritis across all litters has been
broadly spread (31–493 d from birth). A number of lines
have now been inbred by mating siblings. In the F2 litters,
the age range over which animals became ill was 57–199 d.
We have subsequently found that the age of onset of veri-
fied arteritis appears to be heritable. In one highly suscepti-
ble lineage of animals, all 38 Il1rn2/2 mice died at a mean
age of 103 d (SD 5 27 d). These animals were initially
reared in quarantine rather than SPF conditions, but upon
rederivation into SPF conditions the homozygotes of the
first litter from this lineage also died very early. In a much
less susceptible lineage, five of five Il1rn2/2 mice died at
.350 d, but arteritis was seen in all of them. The presence
of extensive fibrous, repaired lesions in aged survivors sug-
gests that they were able to survive with arteritis rather than
failed to develop the disease.
Mild Disease in Il1rn1/2 Mice.  Overt illness has been very
rare in heterozygous mice, so to compare the incidence of
arteritis in heterozygous and homozygous animals, we in-
vestigated outwardly healthy littermates of both genotypes.
Arteritis was found in six of nine Il1rn2/2 animals (age range
112–130 d). Examination of a set of overtly healthy heterozy-
gous animals has also revealed small lesions in 8/17 animals
(age range, 105–158 d). To demonstrate that lesions were
not merely endemic and aggravated in IL-1ra–deficient
mice, we raised wild-type animals from the most susceptible
lineage for comparison with their Il1rn2/2 littermates. No
lesions were found in 11 wild-type animals (age range,
127–190 d). All 11 Il1rn2/2 littermates (age range, 82–149 d)
had arteritic lesions, and 7 had died before their wild-type
littermates were culled.
Localization of Arteritic Lesions. Arteritis was found in the
aorta and in its primary and secondary branches. Lesions
have not been found in veins or capillaries or in smaller ar-
teries, such as those of the kidney, that are typically affected
by polyarteritis nodosa. Only one lesion in a pulmonary ar-
tery has recently been discovered. Full arterial examination
of Il1rn2/2 animals (regardless of the cause of death) re-
vealed lesions in 49/55 mice, and we frequently observed
thoracic lesions (33/55) at the aortic root (12/55), in one
or more coronary arteries (18/55), or affecting other vessels
of the mediastinum (12/55). The abdominal aorta was af-
fected in 30/55 cases. The iliac bifurcation (4/55) and the
highly flexed popliteal arteries (8/55) were also affected.
Sudden behavioral disorders alerted us to discover cerebral
lesions in two cases. Il1rn2/2 mice often had multiple le-
sions. By comparison, only one lesion was discovered above
the diaphragm in a heterozygote and only 2/17 mice ex-
amined had two lesions.
Nature of the Arteritic Lesions. Fig. 3 illustrates some typ-
ical large lesions from Il1rn2/2 mice. An inflamed right
coronary artery (Fig. 3 a, R) was found to be surrounded
by a massive cellular infiltrate (I) that tracked through the
swollen free wall of the right ventricle, following the ex-
pected path of the vessel. A branch of the left coronary ar-
tery (L) and a nearby vein (V) were unaffected. Higher
magnification (Fig. 3 b) revealed the characteristic whorled
structure of chronic inflammation; the arrow indicates leu-
kocytes apparently adhering to endothelium (see also L and E,
respectively, in Fig. 3 c). The morphology of the medial
cells (Fig. 3 c, M) suggests that smooth muscle was replaced
by or had dedifferentiated into fibroblast-like (synthetic, non-
contractile) cells (24). The chronic nature of the disease is il-
lustrated by the presence of myocardial scarring (Fig. 3 d), in-
dicating previous infarctions, which are uncommon in mice.
The collapse and stenosis or ballooning and rupture of
affected vessels probably results from the destruction of the
elastic laminae. Fig. 3, e and f, shows consecutive glancing
sections of a mesenteric artery stained for cells (Fig. 3 e) and
for elastin and connective tissue (Fig. 3 f). Full-thickness
sections of three adjacent loops of artery are shown. The
leftmost portion of the vessel was unaffected, with compact
adventitia and intact elastic layers. The right portion of the
vessel was severely inflamed, with a massive transmural in-
filtrate of leukocytes (Fig. 3 e), and the elastin layers were
destroyed (Fig. 3 f). A longitudinal section of the adjacent
portion of the aorta (Fig. 3, g and h) shows similar focused
destruction of the elastic lamina. Repaired lesions were also
found in both Il1rn2/2 and Il1rn1/2 mice and were charac-
terized by damaged elastic layers with fibrous scarring but
an absence of infiltrate (data not shown).
The margins of the arteritic lesions appeared to be sharply
Figure 2. Mortality and disease in mice carrying the Il1rn-null allele.
Survival curve during the first 550 d from birth of all IL1rn1/2 (broken
line) and Il1rn2/2 (solid line) mice in the first 18 litters (excluding those
culled as controls for other experiments). The mice either died spontane-
ously or were killed for humane reasons on veterinary advice.307 Nicklin et al.
defined and centered upon flexures, branches, and bifurca-
tions, which are known sites of turbulent blood flow and
have long been recognized as focal sites for atheroma.
Identification of Infiltrating Cells and the Presence of IL-1b.
Immunohistochemistry experiments were done with several
sections each from four fresh-frozen lesions (taken from an
aortic root, a small subclavian aneurysm, and a large carotid
aneurysm, which is shown in Fig. 4). We found abundant
macrophages (Fig. 4 c) and CD41 T cells (Fig. 4 d) in the
media of the vessel wall. CD191 B cells and CD81 T cells
were rarely found (data not shown). Neutrophils, detected
by chloroacetate esterase activity, were also abundant (data
not shown).
We have proposed that the formation of arterial lesions is
mediated by the presence of unopposed IL-1. To demon-
strate its presence at lesional sites, we performed immuno-
histochemistry on saponin-treated frozen sections of three
arterial lesions from Il1rn2/2 animals with antibodies spe-
cific to mouse IL-1b (Fig. 4 b). Simultaneous detection of
the macrophage-specific antigen F4/80 (red staining) and
IL-1b (dark brown staining) suggested that many, but not
necessarily all, of the cells that were strongly positive for
IL-1b were macrophages (Fig. 4, e and g). This population
was generally found deep within the vessel wall (examples
are labeled M2 in Fig. 4 g). Macrophages were clearly very
abundant, but not all of them are activated to express IL-1b;
Figure 3. Arterial inflammation
in Il1rn2/2 mice. (a–d) Localized
severe inflammation of a coronary
artery. A section has been cut
through the pulmonary outflow
of an affected 182-d-old Il1rn2/2
mouse and stained with hematox-
ylin and eosin. (a) Low magnifica-
tion. Arrows indicate a grossly in-
flamed right coronary artery (R),
inflammatory infiltrate surround-
ing the track of the artery out of
the plane of the section (I), unaf-
fected left coronary artery (L), and
an unaffected vein (V). (b and c)
Higher magnifications of the cor-
onary lesion showing whorled in-
flammatory infiltrate and leuko-
cytes (L, arrow) adhering to the
endothelium (E) and relatively
undifferentiated mesenchymal cells
(M). (d) Myocardial scar from the
same section. (e–h) Typical le-
sions, showing localized transmu-
ral destruction of arterial walls. (e
and f) Sequential glancing sections
were cut through the wall of an
affected mesenteric artery from a
72-d-old  Il1rn2/2 mouse and
stained for cells with hematoxylin
and eosin (e) and for elastin and
connective tissue fibrils with elas-
tin van Gieson’s stain (f). Three
increasingly affected loops of the
artery are visible. In panel e, note
that the smooth muscle layer be-
comes expanded and progressively
disorganized (left to right). Inflam-
matory infiltrate, filling much of
the field, surrounds the last loop.
In panel f, note that the two layers
of elastic tissue that surround the
first and second loops are com-
pletely absent from the third.
Also, loose connective tissue of
the tunica adventitia (which stains
red) surrounds the first loop
closely but is dispersed by the in-
filtration around the third loop. (g
and h) Corresponding staining of
a longitudinal section of an aortic
lesion from the same mouse,
showing localized damage and di-
lation of the vessel.308 Arteritis in IL-1ra–deficient Mice
notably, a band of cells (labeled M1 in Fig. 4 c) that sur-
rounded much of the lumen were strongly F4/80 positive
but contained no IL-1b (labeled M1 in Fig. 4 e). For clar-
ity, no nuclear counterstain was used in panels e and h, but
a comparison can be made with panels a–d, in which he-
matoxylin was used. CD41 T cells are also abundant, but
less so than macrophages, and were found dispersed through
the lesional wall. They did not appear to accumulate as
densely as the IL-1b2 macrophages (M1) found close to the
lumen. In Fig. 4, f and h, it seems likely that IL-1b–express-
ing cells were associated with CD41 cells, suggesting that
the CD41 cells might be involved, within the wall of the
aneurysm, in activating IL-1b production in the dispersed
macrophages and that, in turn, these cells might be activat-
ing the CD41 cells, possibly through the presentation of
autoantigens.
We have looked for signs of humoral autoimmunity in
the sera of three severely affected animals, a control wild-type
Figure 4. Immunohistochemical
analysis of an aneurysm from a 95-d-
old  Il1rn2/2 mouse. Serial frozen
sections were probed with specific
antibodies to detect IL-1b, CD4,
and the macrophage-specific marker
F4/80 antigen. Comparable areas
of the sections are shown. The lu-
menal face of the lesion is marked
L. (a) Hematoxylin/eosin-stained
section, showing the densely cellu-
lar vessel wall. (b) A section stained
for IL-1b expression (brown),
counterstained with hematoxylin.
(c) A section stained for F4/80 anti-
gen expression (brown) and coun-
terstained with hematoxylin. Note
the dense band of macrophages
(M1) flanking the lumen and dis-
persed macrophages throughout
the lesion. (d) A section stained for
CD4 antigen (brown) and counter-
stained with hematoxylin. CD41
cells are dispersed through the wall
of the lesion. (e) Dual staining of a
lesional site for IL-1b (dark
brown) and the macrophage-spe-
cific F4/80 antigen (red). Note the
belt of IL-1b2 macrophages (M1)
adjacent to the lumen (L). (f) Dual
staining of a lesional site for IL-1b
(dark brown) and CD41 T cells
(red). (g) Higher magnification of
the same section as in e, showing
cells (labeled M2) that appear to
contain both red stain from the de-
tection of F4/80 antigen and dark
brown stain from IL-1b. (h)
Higher magnification of the same
section as in f, showing CD41 (red)
and IL-1b–expressing cells (dark
brown).309 Nicklin et al.
and an MRL/lpr mouse, as a positive control, by standard
antinuclear antigen assays on Hep-2 cells (Immuno Con-
cepts, Inc.). We detected bound antinuclear antibodies with
FITC-conjugated F(ab)2 from goat anti–mouse IgG plus
IgM. We found no evidence for antinuclear antibodies in
the Il1rn2/2 mouse serum, though they were abundant in
the MRL/lpr serum. 
Discussion
We have eliminated a functional gene for IL-1ra in mice
and have found reproducible development of lethal inflam-
matory lesions at high stress sites in the major arteries. Tur-
bulent flow causes fluctuating shear stress in vessel walls and
has been suggested to alter vascular gene activation directly,
leading to increased leukocyte adherence to endothelial
cells (32), and thus might result in increased leukocyte traf-
fic through the vessel wall. Irregular flow may also allow
deposition of bacterial pathogens or proinflammatory de-
bris, including oxidized lipids, at turbulent sites. It has been
shown that oxidized lipids can, for instance, activate chemo-
kine expression in endothelium (33). Turbulence probably
also causes increased localized damage, particularly desqua-
mation of the endothelium and local inflammation (24). Fur-
ther studies will be needed to establish whether IL-1 is ex-
pressed in mice only at sites of localized arterial damage or
whether it is generally induced at sites of stress within
healthy vessel walls.
In its transmural destructiveness, the disease that we have
observed resembles human giant cell arteritis and poly-
arteritis nodosa. The former has a similar pattern of distri-
bution within arteries but is normally characterized by fre-
quent giant macrophages, which are rare in the animal disease.
In 42 affected Il1rn2/2 animals, we have detected no active
inflammation of the arteries of the kidney, which is a com-
mon feature of the latter. Human arterial disease and arter-
itides have been linked to microbial pathogens, and there
has been recent interest in Helicobacter spp. and Chlamydia in
coronary disease. Similarly cytomegalovirus causes arteritis
in mice, although the pathological features are different
from those reported here (34). Our colony was initially es-
tablished under quarantine (not SPF) conditions, but up to
the time of this writing (now seven generations after re-
derivation into SPF conditions), Il1rn2/2 mice have contin-
ued to develop lethal arteritis. Tests for an array of viral and
bacterial pathogens (see Materials and Methods) showed
that all pathogens investigated were absent, with the excep-
tion of H. hepaticus, which we have detected in both our
colony and that of Hirsch et al. (27), where vascular disease
was not found. The bacterium appears to colonize litter-
mates of all genotypes. We are, however, currently investi-
gating the influence of the resident bacterial flora on the
occurrence of arteritis.
A pattern of early mortality has emerged among Il1rn2/2
animals (backcrossed onto a C57BL/6 background) from
the US group (Hirsch, E., and D. Hirsh, personal com-
munication) and illness in animals from the Japanese group,
who bred their mice onto a Balb/c background (Iwakura, Y.,
personal communication). We have now examined speci-
mens from the US group (backcrossed 15 times onto
C57BL/6) but have not found evidence for arteritic lesions
at the commonly affected sites in six Il1rn2/2 specimens
provided (aged 175–427 d), despite overt malaise in four of
six cases. The cause of high mortality in the US Il1rn2/2
animals is thus not explained.
It is noteworthy that the Il1rn2/2 Balb/c mice, after the
fourth backcross, spontaneously develop a quite different
chronic inflammatory pathology, namely arthritis, in 80% of
cases before they are 56 d old (Iwakura, Y., personal com-
munication). We have examined bones and joints of 42
Il1rn2/2 animals from our colony, all of which were older
than 56 d, and have not detected arthritis, nor have we ob-
served external signs of joint disease in the living animals.
At least a part of the cause of the difference between the
three Il1rn-null colonies is likely to stem from differences
in their genetic backgrounds. We have seen that extreme
susceptibility is heritable and survives rederivation into SPF
conditions, a procedure that would be expected to cause a
change of microbial flora. Moreover, the phenotype that
we observe is stable and continues to occur at a very high
frequency in Il1rn2/2 animals in our colony more than 2 yr
since its first detection. It is unlikely that we have selected a
susceptibility-causing mutation, unless it is present in the
E14 TG2A stem cell line, because our second Il1rn-null
line on an MF1 3 129/Ola background has also developed
disease, yet the MF1 came from a separate colony and the
chimera was derived from a different G418-resistant clone.
Because heterozygotes develop mild disease, we suggest
that the IL-1ra gene is haploinsufficient. This is plausible
because of the unusual function of the IL-1ra protein, act-
ing solely as a competitive inhibitor of IL-1. Its concentra-
tion at an inflamed site is therefore likely to be critical to its
efficacy, and, in the absence of sufficient compensatory reg-
ulation, it is likely to achieve a maximum in the heterozy-
gote of only half of the wild-type level. An alternative ex-
planation, however, might be that we have unwittingly
created a hypomorphic allele, although there is no obvious
reason for the truncated open reading frame of IL-1ra
(which is a single domain protein) to be expected to yield a
dominant negative species.
We conclude that IL-1ra is required in our mouse col-
ony to prevent the development of lethal arteritis. Because
the only known function of IL-1ra is to antagonize the ac-
tivity of IL-1, our working hypothesis is that the disease is
caused by the unopposed action of IL-1. IL-1 induces a
wave of release, from many cells within the affected tissue,
of chemokines and proinflammatory cytokines that would
recruit further inflammatory cells. In the absence of IL-1ra
activity, this would amplify the unbalanced response. IL-1
might initially be released spontaneously by stressed smooth
muscle or endothelial cells or by macrophages (possibly ini-
tially triggered by bacterial infection or oxidized lipid depo-
sition) in the walls of high pressure vessels in areas of high
turbulence. We have shown that macrophages are abun-
dant in established lesions, many having cytoplasmic loads
of IL-1, and that CD41 T cells are present. It seems very310 Arteritis in IL-1ra–deficient Mice
likely that later IL-1 production from macrophages in es-
tablished lesions occurs as a result of their activation by
CD41 T cells, and we speculate that the latter might be au-
toreactive. We have found no evidence of an autoreactive
humoral response. We are currently confirming the essen-
tial role of IL-1 in the phenotype by crossing Il1rn-null
animals with mice that lack the IL-1 receptor (35). The dis-
ease we observe in IL-1ra–deficient mice may offer an op-
portunity to dissect important pathophysiological mecha-
nisms occurring in large arteries.
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